Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine

Park, Jong Myun, Terabe, Masaki, Steel, Jason C., Forni, Guido, Sakai, Yoshio, Morris, John C. and Berzofsky, Jay A. (2008) Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Research, 68 6: 1979-1987. doi:10.1158/0008-5472.CAN-07-5688


Author Park, Jong Myun
Terabe, Masaki
Steel, Jason C.
Forni, Guido
Sakai, Yoshio
Morris, John C.
Berzofsky, Jay A.
Title Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine
Formatted title
Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine
Journal name Cancer Research   Check publisher's open access policy
ISSN 0008-5472
1538-7445
Publication date 2008-03-01
Sub-type Article (original research)
DOI 10.1158/0008-5472.CAN-07-5688
Open Access Status Not yet assessed
Volume 68
Issue 6
Start page 1979
End page 1987
Total pages 9
Place of publication Philadelphia, PA, United States
Publisher American Association for Cancer Research
Language eng
Formatted abstract
ErbB-2 (HER-2/neu) is a transforming oncogene expressed by a substantial fraction of breast cancers, and monoclonal antibody therapy directed toward this antigen is an established treatment modality. However, not all tumors respond, and with a monoclonal antibody directed to a single epitope, there is always the risk of tumor escape. Furthermore, passive antibody therapy requires continual treatment. Whereas cancer vaccines have prevented the growth of tumors, it has been far more difficult to treat large established tumors. Here, we show that vaccination with a recombinant adenovirus expressing a truncated ErbB-2 antigen can cure large established subcutaneous ErbB-2-expressing breast cancers in mice, and can also cure extensive established lung metastatic disease. We also show that the mechanism of protection involves antibody-mediated blockade of ErbB-2 function, independent of Fc receptors. We conclude that a vaccine inducing antibodies to a functional oncogenic receptor could have tremendous therapeutic potential against cancers overexpressing such molecules.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 23 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 18 Mar 2015, 02:07:19 EST by Jason Steel on behalf of Learning and Research Services (UQ Library)